Biogen, mRNA players on Merck's M&A radar as CEO still hungry for deals after $11.5B Acceleron buy: FT

Merck & Co. remains in a deal-hunting mode despite its recent $11.5 billion acquisition for Acceleron. Merck CEO Rob Davis is actively piecing together a plan for life after Keytruda, and the company seems to already have a list of potential targets.